Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
AssigneesPfizer Inc., Merck Sharp & Dohme Corp.
InventorsJean-Francois Andre Martini, Jamal Christo Tarazi, Rodolfo Fleury Perini, David J. Mauro
Life of this patent
Estimating the term…
Abstract
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
Claims19
A method for treating a renal cell carcinoma (RCC) in an individual comprising administering to the individual a combination therapy which comprises pembrolizumab and axitinib,
- wherein the individual has not been previously treated for RCC,
- wherein axitinib is administered at a starting dose of 5 mg twice daily (BID), and
- wherein if the individual tolerates axitinib with no drug-related grade >2 adverse events for two consecutive weeks, the dose of axitinib is then increased to a maximum dose of 10 mg BID.
A method for treating a renal cell carcinoma (RCC) in an individual comprising administering to the individual a combination therapy which comprises pembrolizumab and axitinib,
- wherein the individual has not been previously treated for RCC,
- wherein axitinib is administered at a starting dose of 5 mg BID, and
- wherein if the dose combination is not tolerated by the individual, the dose of axitinib is then reduced to a minimum dose of 3 mg BID.
Dependencies are inferred from the claim text.